Alan Brennan

List of Publications by Year in Descending Order

190 papers	5,259 citations	40 h-index	66 g-index
231 ext. papers	6,165 ext. citations	4.5 avg, IF	5.66 L-index

#	Paper	IF	Citations
190	Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application.. *BMJ Open*, **2022**, 12, e051651	3	0
189	Development of a Web-Based, Guided Self-help, Acceptance and Commitment Therapy-Based Intervention for Weight Loss Maintenance: Evidence-, Theory-, and Person-Based Approach.. *JMIR Formative Research*, **2022**, 6, e31801	2.5	2
188	An integrated dual process simulation model of alcohol use behaviours in individuals, with application to US population-level consumption, 1984-2012. *Addictive Behaviors*, **2022**, 124, 107094	4.2	1
187	Acceptability and feasibility of an acceptance and commitment therapy-based guided self-help intervention for weight loss maintenance in adults who have previously completed a behavioural weight loss programme: the SWiM feasibility study protocol.. *BMJ Open*, **2022**, 12, e058103	3	0
186	Controlled observational study and economic evaluation of the effect of city-centre night-time alcohol intoxication management services on the emergency care system compared with usual care. *Emergency Medicine Journal*, **2021**, 38, 504-510	1.5	0
185	Quantile regression of tobacco tax pass-through in the UK 2013-2019. How have manufacturers passed through tax changes for different tobacco products?. *Tobacco Control*, **2021**, 30, e27-e32	5.3	3
184	Developing logic models to inform public health policy outcome evaluation: an example from tobacco control. *Journal of Public Health*, **2021**, 43, 639-646	3.5	0
183	Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. *Medical Decision Making*, **2021**, 272989X211045036	2.5	0
182	Potential effects of minimum unit pricing at local authority level on alcohol-attributed harms in North West and North East England: a modelling study. *Public Health Research*, **2021**, 9, 1-106	1.7	0
181	Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes. *British Journal of Surgery*, **2021**, 108, 315-325	5.3	2
180	Alcohol policy and gender: a modelling study estimating gender-specific effects of alcohol pricing policies. *Addiction*, **2021**, 116, 2372-2384	4.6	2
179	POS0734 EXTRAPOLATION OF LONG-TERM OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: REPLICATING A HOPKINS LUPUS COHORT ANALYSIS WITH THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT. *Annals of the Rheumatic Diseases*, **2021**, 80, 617.2-618	2.4	0
178	Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer. *British Journal of Cancer*, **2021**, 125, 209-219	8.7	6
177	Cost-Effectiveness Modeling of Surgery Plus Adjuvant Endocrine Therapy Versus Primary Endocrine Therapy Alone in UK Women Aged 70 and Over With Early Breast Cancer. *Value in Health*, **2021**, 24, 770-779	3.3	0
176	Promoting physical activity in a multi-ethnic population at high risk of diabetes: the 48-month PROPELS randomised controlled trial. *BMC Medicine*, **2021**, 19, 130	11.4	1
175	Commentary on Robinson et al. (2021): Evaluating theories of change for public health policies using computer model discovery methods. *Addiction*, **2021**, 116, 2709-2711	4.6	
174	Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life. *European Journal of Cancer*, **2021**, 142, 48-62	7.5	10

#	Reference		
173	The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?. *European Journal of Health Economics*, **2021**, 22, 381-392	3.6	0
172	Conceptualising changes to tobacco and alcohol policy as affecting a single interlinked system. *BMC Public Health*, **2021**, 21, 17	4.1	
171	Using Multi-objective Grammar-based Genetic Programming to Integrate Multiple Social Theories in Agent-based Modeling. *Lecture Notes in Computer Science*, **2021**, 12654, 721-733	0.9	1
170	Do dual purchasers behave differently? An analysis of purchasing data for households that buy both alcohol and tobacco in the United Kingdom. *Addiction*, **2021**, 116, 2538-2547	4.6	1
169	Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. *European Journal of Cancer*, **2021**, 144, 269-280	7.5	14
168	Observational cohort study in older women with early breast cancer: Use of radiation therapy and impact on health-related quality of life and mortality. *Radiotherapy and Oncology*, **2021**, 161, 166-176	5.3	1
167	Understanding long-term trends in smoking in England, 1972-2019: an age-period-cohort approach. *Addiction*, **2021**,	4.6	2
166	Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT.. *Health Technology Assessment*, **2021**, 25, 1-190	4.4	0
165	Clinical and cost-effectiveness of a diabetes education and behavioural weight management programme versus a diabetes education programme in adults with a recent diagnosis of type 2 diabetes: study protocol for the Glucose Lowering through Weight management (GLoW) randomised controlled trial. *BMJ Open*, **2020**, 10, e035020	3	1
164	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. *Value in Health*, **2020**, 23, 734-742	3.3	20
163	Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data. *Value in Health*, **2020**, 23, 743-750	3.3	1
162	Expanding attributable fraction applications to outcomes wholly attributable to a risk factor. *Statistical Methods in Medical Research*, **2020**, 29, 2637-2646	2.3	3
161	How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. *Trials*, **2020**, 21, 252	2.8	2
160	The Normative Underpinnings of Population-Level Alcohol Use: An Individual-Level Simulation Model. *Health Education and Behavior*, **2020**, 47, 224-234	4.2	8
159	Reweighting national survey data for small area behaviour estimates: modelling alcohol consumption in Local Authorities in England. *Population Health Metrics*, **2020**, 18, 1	3	7
158	Modelling the effects of alcohol pricing policies on alcohol consumption in subpopulations in Australia. *Addiction*, **2020**, 115, 1038-1049	4.6	7
157	Systematic review and meta-analysis of randomized controlled trials of psychological interventions to improve glycaemic control in children and adults with type 1 diabetes. *Diabetic Medicine*, **2020**, 37, 735-746	3.5	9
156	Psychological interventions to improve glycemic control in adults with type 2 diabetes: a systematic review and meta-analysis. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	6

#	Reference	IF	Cites
155	A software architecture for mechanism-based social systems modelling in agent-based simulation models. *Jasss*, **2020**, 23,	4.8	9
154	The impact of promoting revised UK low-risk drinking guidelines on alcohol consumption: interrupted time series analysis. *Public Health Research*, **2020**, 8, 1-108	1.7	
153	Evaluating alcohol intoxication management services: the EDARA mixed-methods study. *Health Services and Delivery Research*, **2020**, 8, 1-214	1.5	2
152	Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. *Health Technology Assessment*, **2020**, 24, 1-232	4.4	11
151	Introducing CASCADEPOP: an open-source sociodemographic simulation platform for us health policy appraisal **2020**, 13, 21-60		4
150	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. *Pharmacoeconomics*, **2020**, 38, 193-204	4.4	9
149	A Systematic Review of Methods to Predict Weight Trajectories in Health Economic Models of Behavioral Weight-Management Programs: The Potential Role of Psychosocial Factors. *Medical Decision Making*, **2020**, 40, 90-105	2.5	1
148	The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease. *Medical Decision Making*, **2020**, 40, 912-923	2.5	0
147	Multiobjective Genetic Programming Can Improve the Explanatory Capabilities of Mechanism-Based Models of Social Systems. *Complexity*, **2020**, 2020,	1.6	7
146	Assessing the contribution of alcohol-specific causes to socio-economic inequalities in mortality in England and Wales 2001-16. *Addiction*, **2020**, 115, 2268-2279	4.6	9
145	Effects on alcohol consumption of announcing and implementing revised UK low-risk drinking guidelines: findings from an interrupted time series analysis. *Journal of Epidemiology and Community Health*, **2020**, 74, 942-949	5.1	3
144	Toward inverse generative social science using multi-objective genetic programming **2019**, 2019, 1356-1363		12
143	Modeling the Potential Impact of Changing Access Rates to Specialist Treatment for Alcohol Dependence for Local Authorities in England: The Specialist Treatment for Alcohol Model (STreAM). *Journal of Studies on Alcohol and Drugs Supplement*, **2019**, Sup 18, 96-109	3.9	11
142	Migraine day frequency in migraine prevention: longitudinal modelling approaches. *BMC Medical Research Methodology*, **2019**, 19, 20	4.7	2
141	The effects of alcohol pricing policies on consumption, health, social and economic outcomes, and health inequality in Australia: a protocol of an epidemiological modelling study. *BMJ Open*, **2019**, 9, e029918	3	4
140	Examining the relationship between energy poverty and measures of deprivation. *Energy Policy*, **2019**, 130, 206-217	7.2	16
139	A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. *Value in Health*, **2019**, 22, 391-398	3.3	10
138	How should we set consumption thresholds for low risk drinking guidelines? Achieving objectivity and transparency using evidence, expert judgement and pragmatism. *Addiction*, **2019**, 114, 590-600	4.6	16

137	Effects on alcohol consumption of announcing revised UK low-risk drinking guidelines: findings from a monthly cross-sectional survey. *Lancet, The*, **2019**, 394, S54	40	2
136	Cost-effectiveness of strategies to improve delivery of brief interventions for heavy drinking in primary care: results from the ODHIN trial. *European Journal of Public Health*, **2019**, 29, 219-225	2.1	3
135	Processes of local alcohol policy-making in England: Does the theory of policy transfer provide useful insights into public health decision-making?. *Health and Place*, **2019**, 57, 358-364	4.6	7
134	Commentary on Apostolopoulos et al. (2018): Systems and complex systems approaches for public health planning-back to the future?. *Addiction*, **2018**, 113, 372-373	4.6	2
133	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. *Value in Health*, **2018**, 21, 724-731	3.3	44
132	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. *Journal of Medical Economics*, **2018**, 21, 666-675	2.4	21
131	How dependent is the alcohol industry on heavy drinking in England?. *Addiction*, **2018**, 113, 2225-2232	4.6	20
130	Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. *BMJ Open*, **2018**, 8, e016766	3	15
129	Alcohol Screening and Brief Intervention in Police Custody Suites: Pilot Cluster Randomised Controlled Trial (AcCePT). *Alcohol and Alcoholism*, **2018**, 53, 548-559	3.5	7
128	The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. *Diabetic Medicine*, **2017**, 34, 632-640	3.5	15
127	Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews. *Pharmacoeconomics*, **2017**, 35, 937-949	4.4	43
126	Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. *Diabetic Medicine*, **2017**, 34, 1136-1144	3.5	21
125	Understanding the alcohol harm paradox: an analysis of sex- and condition-specific hospital admissions by socio-economic group for alcohol-associated conditions in England. *Addiction*, **2017**, 112, 808-817	4.6	18
124	Typology and Dynamics of Heavier Drinking Styles in Great Britain: 1978-2010. *Alcohol and Alcoholism*, **2017**, 52, 372-381	3.5	2
123	Estimating the cost-effectiveness of brief interventions for heavy drinking in primary health care across Europe. *European Journal of Public Health*, **2017**, 27, 345-351	2.1	18
122	Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. *BMJ Open*, **2017**, 7, e014953	3	17
121	The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. *Pharmacoeconomics*, **2017**, 35, 1287-1296	4.4	27
120	The intervention effect of local alcohol licensing policies on hospital admission and crime: a natural experiment using a novel Bayesian synthetictime-series method. *Journal of Epidemiology and Community Health*, **2017**, 71, 912-918	5.1	30

119	Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment. *Pharmacoeconomics*, **2017**, 35, 989-1006	4.4	8
118	Testing the impact of local alcohol licencing policies on reported crime rates in England. *Journal of Epidemiology and Community Health*, **2017**, 71, 137-145	5.1	28
117	Mapping Patterns and Trends in the Spatial Availability of Alcohol Using Low-Level Geographic Data: A Case Study in England 2003-2013. *International Journal of Environmental Research and Public Health*, **2017**, 14,	4.6	9
116	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. *Health Technology Assessment*, **2017**, 21, 1-278	4.4	31
115	Developing policy analytics for public health strategy and decisions-the Sheffield alcohol policy model framework. *Annals of Operations Research*, **2016**, 236, 149-176	3.2	13
114	The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes. *Medical Decision Making*, **2016**, 36, 1020-33	2.5	24
113	Local policies to tackle a national problem: Comparative qualitative case studies of an English local authority alcohol availability intervention. *Health and Place*, **2016**, 41, 11-18	4.6	20
112	Comparison of brief interventions in primary care on smoking and excessive alcohol consumption: a population survey in England. *British Journal of General Practice*, **2016**, 66, e1-9	1.6	65
111	Are recent attempts to quit smoking associated with reduced drinking in England? A cross-sectional population survey. *BMC Public Health*, **2016**, 16, 535	4.1	8
110	Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England. *BMC Public Health*, **2016**, 16, 917	4.1	17
109	Propensity score matching for selection of local areas as controls for evaluation of effects of alcohol policies in case series and quasi case-control designs. *Public Health*, **2016**, 132, 40-9	4	8
108	Measurable effects of local alcohol licensing policies on population health in England. *Journal of Epidemiology and Community Health*, **2016**, 70, 231-7	5.1	35
107	A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study. *Journal of Public Health*, **2016**, 38, 679-687	3.5	11
106	Deconstructing the Alcohol Harm Paradox: A Population Based Survey of Adults in England. *PLoS ONE*, **2016**, 11, e0160666	3.7	45
105	P66 Cross-sectional and longitudinal associations between alcohol licensing policies, outlet density and deprivation and population health and crime in England. *Journal of Epidemiology and Community Health*, **2016**, 70, A83.1-A83	5.1	
104	Estimated Effects of Different Alcohol Taxation and Price Policies on Health Inequalities: A Mathematical Modelling Study. *PLoS Medicine*, **2016**, 13, e1001963	11.6	69
103	An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. *Addiction*, **2016**, 111, 1616-27	4.6	6
102	COST-EFFECTIVENESS OF STRUCTURED EDUCATION IN CHILDREN WITH TYPE-1 DIABETES MELLITUS. *International Journal of Technology Assessment in Health Care*, **2016**, 32, 203-211	1.8	1

101	Parametric Simulation of Headache Day Frequency Using A Negative Binomial Distribution: A Case Study of Erenumab in Episodic Migraine. *Value in Health*, **2016**, 19, A361	3.3	2
100	Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. *Value in Health*, **2016**, 19, 404-12	3.3	11
99	Developing a social practice-based typology of British drinking culture in 2009-2011: implications for alcohol policy analysis. *Addiction*, **2016**, 111, 1568-79	4.6	69
98	Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method. *Medical Decision Making*, **2015**, 35, 570-83	2.5	68
97	Protocol for a national monthly survey of alcohol use in England with 6-month follow-up: the Alcohol Toolkit Study. *BMC Public Health*, **2015**, 15, 230	4.1	41
96	A pilot feasibility trial of alcohol screening and brief intervention in the police custody setting (ACCEPT): study protocol for a cluster randomised controlled trial. *Pilot and Feasibility Studies*, **2015**, 1, 6	1.9	4
95	Estimating the measurable impact of local alcohol licensing policies on population health in England using ecological longitudinal data. *Lancet, The*, **2015**, 386, S33	40	2
94	Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models: A Case Study in Type 1 Diabetes. *Medical Decision Making*, **2015**, 35, 872-87	2.5	1
93	An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. *Rheumatology*, **2015**, 54, 623-32	3.9	14
92	The Sheffield Alcohol Policy Model - A Mathematical Description. *Health Economics (United Kingdom)*, **2015**, 24, 1368-1388	2.4	26
91	Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing. *Health Economics (United Kingdom)*, **2015**, 24, 1468-82	2.4	8
90	A theory-based online health behaviour intervention for new university students (U@Uni:LifeGuide): results from a repeat randomized controlled trial. *Trials*, **2015**, 16, 555	2.8	35
89	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. *Health Technology Assessment*, **2015**, 19, 1-80	4.4	17
88	Agile Development of an Attitude-Behaviour Driven Simulation of Alcohol Consumption Dynamics. *Jasss*, **2015**, 18,	4.8	3
87	Cost-effectiveness of a programme of screening and brief interventions for alcohol in primary care in Italy. *BMC Family Practice*, **2014**, 15, 26	2.6	23
86	Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods. *Applied Health Economics and Health Policy*, **2014**, 12, 239-53	3.4	15
85	Estimation of usual occasion-based individual drinking patterns using diary survey data. *Drug and Alcohol Dependence*, **2014**, 134, 136-143	4.9	6
84	Layering Interventions for Type-2 Diabetes Prevention Using The Sphr Diabetes Model. *Value in Health*, **2014**, 17, A347	3.3	1

83	A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trial. *BMC Public Health*, **2014**, 14, 563	4.1	47
82	Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. *Lancet, The*, **2014**, 383, 1655-1664	40	171
81	Estimation of own and cross price elasticities of alcohol demand in the UK--A pseudo-panel approach using the Living Costs and Food Survey 2001-2009. *Journal of Health Economics*, **2014**, 34, 96-103	2.5	53
80	Evolutionary parameter estimation for a theory of planned behaviour microsimulation of alcohol consumption dynamics in an English birth cohort 2003 to 2010 **2014**,		3
79	Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study. *BMJ, The*, **2014**, 349, g5452	5.9	37
78	Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. *Medical Decision Making*, **2014**, 34, 311-26	2.5	158
77	The impact of spatial and temporal availability of alcohol on its consumption and related harms: a critical review in the context of UK licensing policies. *Drug and Alcohol Review*, **2014**, 33, 515-25	3.2	54
76	Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. *Diabetic Medicine*, **2014**, 31, 477-86	3.5	21
75	Alcohol tax pass-through across the product and price range: do retailers treat cheap alcohol differently?. *Addiction*, **2014**, 109, 1994-2002	4.6	28
74	Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. *Diabetic Medicine*, **2014**, 31, 847-53	3.5	74
73	The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation. *BMC Public Health*, **2014**, 14, 1011	4.1	8
72	Trend analysis and modelling of gender-specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in Great Britain using the General Lifestyle Survey 1984-2009. *Addiction*, **2014**, 109, 206-15	4.6	88
71	Reporting the characteristics of the policy context for population-level alcohol interventions: a proposed Transparent Reporting of Alcohol Intervention ContExtsS(TRAICE) checklist. *Drug and Alcohol Review*, **2014**, 33, 596-603	3.2	3
70	Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the	1.5	22
69	A theory-based online health behavior intervention for new university students: study protocol. *BMC Public Health*, **2013**, 13, 107	4.1	16
68	Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community. *BMC Health Services Research*, **2013**, 13, 150	2.9	9
67	The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies. *European Journal of Health Economics*, **2013**, 14, 887-99	3.6	4
66	Telemonitoring After Discharge from Hospital with Heart Failure Cost-Effectiveness Modelling of Alternative Service Designs. *Value in Health*, **2013**, 16, A530	3.3	3

65	Cost-effectiveness modelling of telemonitoring after discharge from hospital with heart failure. *Value in Health*, **2013**, 16, A290	3.3	2
64	Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model. *Value in Health*, **2013**, 16, 542-53	3.3	15
63	Adjusting for unrecorded consumption in survey and per capita sales data: quantification of impact on gender- and age-specific alcohol-attributable fractions for oral and pharyngeal cancers in Great Britain. *Alcohol and Alcoholism*, **2013**, 48, 241-9	3.5	35
62	Does an intensive self-management structured education course improve outcomes for children and young people with type 1 diabetes? The Kids In Control OF Food (KICk-OFF) cluster-randomised controlled trial protocol. *BMJ Open*, **2013**, 3,	3	12
61	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. *BMJ Open*, **2013**, 3, e003250	3	33
60	Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England. *Alcohol and Alcoholism*, **2013**, 48, 180-8	3.5	54
59	The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model. *Diabetic Medicine*, **2013**, 30, 1236-44	3.5	29
58	Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. *Health Technology Assessment*, **2013**, 17, 1-207, v-vi	4.4	76
57	Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. *Value in Health*, **2012**, 15, 1127-36	3.3	30
56	Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. *Medical Decision Making*, **2012**, 32, 701-11	2.5	130
55	The temporal relationship between per capita alcohol consumption and harm: a systematic review of time lag specifications in aggregate time series analyses. *Drug and Alcohol Dependence*, **2012**, 123, 7-14	4.9	62
54	Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. *Value in Health*, **2012**, 15, 821-7	3.3	143
53	Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. *Health Technology Assessment*, **2012**, 16, 1-236, iii-iv	4.4	81
52	MO3 A Methodological Framework for Developing Models of Whole Disease Areas to Inform Resource Allocation Decisions. *Value in Health*, **2011**, 14, A243	3.3	5
51	Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. *International Journal of Geriatric Psychiatry*, **2011**, 26, 483-94	2.9	14
50	Estimating expected value of sample information for incomplete data models using Bayesian approximation. *Medical Decision Making*, **2011**, 31, 839-52	2.5	12
49	The Sheffield rheumatoid arthritis health economic model. *Rheumatology*, **2011**, 50 Suppl 4, iv26-31	3.9	17
48	Policy options for alcohol price regulation: the importance of modelling population heterogeneity. *Addiction*, **2010**, 105, 383-93	4.6	126

47	POLICY OPTIONS FOR ALCOHOL PRICE REGULATION: RESPONSE TO THE COMMENTARIES. *Addiction*, **2010**, 105, 400-401	4.6	1
46	Decision modeling to inform decision making: seeing the wood for the trees. *Medical Decision Making*, **2010**, 30, E20-2	2.5	3
45	Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. *BMJ, The*, **2010**, 341, c4093	5.9	138
44	A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. *International Journal of Cardiology*, **2010**, 140, 315-22	3.2	7
43	Simulation sample sizes for Monte Carlo partial EVPI calculations. *Journal of Health Economics*, **2010**, 29, 468-77	3.5	42
42	Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. *Lancet, The*, **2010**, 375, 1355-64	40	170
41	The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. *Medical Decision Making*, **2009**, 29, 678-89	2.5	17
40	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. *Pharmaceutical Statistics*, **2009**, 8, 150-62	1	7
39	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. *Pharmaceutical Statistics*, **2009**, 8, 371-89	1	15
38	Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom. *International Journal of Technology Assessment in Health Care*, **2009**, 25, 470-8	1.8	11
37	Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2008**, 115, 749-57	3.7	3
36	Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. *Value in Health*, **2008**, 11, 160-71	3.3	15
35	Comment on: Modelling the cost effectiveness of TNF-antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply. *Rheumatology*, **2008**, 47, 1107-1107	3.9	
34	Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. *Arthritis and Rheumatism*, **2008**, 58, 939-46		70
33	Expected value of sample information for Weibull survival data. *Health Economics (United Kingdom)*, **2007**, 16, 1205-25	2.4	23
32	Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. *Statistics in Medicine*, **2007**, 26, 1237-54	2.2	110
31	The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. *Obesity Reviews*, **2007**, 8, 363-71	10.6	12
30	The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. *Value in Health*, **2007**, 10, 32-41	3.3	27

29	Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. *Medical Decision Making*, **2007**, 27, 448-70	2.5	93
28	Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. *Rheumatology*, **2007**, 46, 1345-54	3.9	88
27	The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. *Rheumatology*, **2007**, 46, 1140-7	3.9	84
26	Efficient computation of partial expected value of sample information using Bayesian approximation. *Journal of Health Economics*, **2007**, 26, 122-48	3.5	43
25	A critique and impact analysis of decision modeling assumptions. *Medical Decision Making*, **2007**, 27, 491-9	2.5	14
24	Screening for type 2 diabetes: literature review and economic modelling. *Health Technology Assessment*, **2007**, 11, iii-iv, ix-xi, 1-125	4.4	183
23	A taxonomy of model structures for economic evaluation of health technologies. *Health Economics (United Kingdom)*, **2006**, 15, 1295-310	2.4	345
22	Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. *Rheumatology*, **2006**, 45, 1029-38	3.9	34
21	A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. *International Journal of Cardiology*, **2006**, 109, 307-16	3.2	20
20	Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. *European Journal of Health Economics*, **2006**, 7, 276-84	3.6	12
19	Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. *Annals of the Rheumatic Diseases*, **2005**, 64, 995-1002	2.4	82
18	Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. *Current Medical Research and Opinion*, **2005**, 21, 101-12	2.5	30
17	Incorporation of uncertainty in health economic modelling studies. *Pharmacoeconomics*, **2005**, 23, 529-36	4.4	45
16	Should patients have a greater role in valuing health states?. *Applied Health Economics and Health Policy*, **2005**, 4, 201-8	3.4	114
15	An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. *Drugs*, **2005**, 65, 473-96	12.1	52
14	Can we use routine data to evaluate organizational change? Lessons from the evaluation of business process re-engineering in a UK teaching hospital. *Health Services Management Research*, **2005**, 18, 265-76	1	8
13	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2005**, 5, 519-29	2.2	4
12	Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. *British Journal of Rheumatology*, **2004**, 43, 62-72		115

11	Cost-effectiveness of sibutramine in the treatment of obesity. *Medical Decision Making*, **2004**, 24, 9-19	2.5	29
10	Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?. *British Journal of Rheumatology*, **2004**, 43, 677-8		5
9	Evaluation of the impact of a technology appraisal process in England: the South and West Development and Evaluation Committee. *Journal of Health Services Research and Policy*, **2003**, 8, 18-24	2.4	5
8	Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials". *European Journal of Health Economics*, **2003**, 4, 239-40	3.6	1
7	Evaluation of the impact of a technology appraisal process in England: the South and West Development and Evaluation Committee. *Journal of Health Services Research and Policy*, **2003**, 8, 18-24	2.4	4
6	The role of modelling in prioritising and planning clinical trials. *Health Technology Assessment*, **2003**, 7, iii, 1-125	4.4	53
5	Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. *Vaccine*, **2002**, 20, 1778-86	4.1	16
4	Triaging patients with serious head injury: results of a simulation evaluating strategies to bypass hospitals without neurosurgical facilities. *Injury*, **2001**, 32, 267-74	2.5	10
3	Is it feasible to plan secondary care services for coronary heart disease rationally? A quantified modelling approach for a UK Health Authority. *Journal of Epidemiology and Community Health*, **2001**, 55, 521-7	5.1	4
2	Modelling in health economic evaluation. What is its place? What is its value?. *Pharmacoeconomics*, **2000**, 17, 445-59	4.4	92
1	Where should new parkrun events be located? Modelling the potential impact of 200 new events on geographical and socioeconomic inequalities in access and participation		6